PremiumCompany AnnouncementsAstraZeneca Deepens Real-World Safety Check on Eplontersen for Amyloidosis18h agoAZN
PremiumRatingsAstraZeneca: Buy Rating Reaffirmed on Robust Pipeline and Attractive Valuation; Price Target Unchanged at $16,50022h agoAZN
AstraZeneca: Buy Rating Reaffirmed on Robust Pipeline and Attractive Valuation; Price Target Unchanged at $16,500